Holen Sie sich die Stockscreener-App
196.50
2.61%
5.00
Vorhandelsmarkt:
198.24
1.74
+0.89%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DHR?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Danaher Corp Aktie (DHR) Neueste Nachrichten
Danaher Corp (DHR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
SCIEX Helps Clinical Labs Move From Sample to Answer Faster With New Software and LC Solutions - 01net
Danaher stock steadies on 2025 revenue and earnings - Ad-hoc-news.de
Danaher stock trades firm as recent earnings highlight diagnostics and life sciences growth - Ad-hoc-news.de
Danaher Corp (DHR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Why Are Danaher (NYSE:DHR) Latest Results Turning Heads? - Kalkine Media
Danaher (DHR) Maintains Buy Rating with $230 Price Target Amid M - GuruFocus
Danaher (DHR) Stock Tries To Steady After A Sharp Post Earnings Selloff - Yahoo Finance
Danaher Corp (DHR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Danaher Corp (DHR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DHR|Danaher Corp|Price:191.500|Chg%:-1.000 - TradingKey
Danaher Corp (DHR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Danaher Corporation (DHR) Stock forecasts - Yahoo Finance UK
Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets - inkl
Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity - The Motley Fool
Danaher Corporation (DHR) Stock Forecasts - Yahoo Finance
Danaher Corp (DHR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Danaher Corp (DHR) Stock Up 7.5% and Still Undervalued -- GF Sco - GuruFocus
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Danaher Corp Stock (DHR) Moved Up by 6.78% on Jul 23: What Signal Does It Send? - TradingKey
Beckman Coulter Diagnostics Launches Fully Automated Urinalysis System to Meet Rising Testing Volumes - Financial Times
DHR Maintains Buy Rating -- Price Target Lowered to $236 by TD C - GuruFocus
DHR Maintained by Guggenheim -- Price Target Lowered to $200 - GuruFocus
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI - Bitget
TD Cowen cuts Danaher stock price target on bioproduction timing By Investing.com - Investing.com South Africa
Danaher stock trades steady as investors weigh life sciences growth and recent margin trends - Ad-hoc-news.de
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
Danaher Corporation (DHR) technical analysisDanaher (NYSE:DHR) - Benzinga
DHR Maintained by Wells Fargo -- Price Target Lowered to $195 - GuruFocus
Stifel cuts Danaher stock price target on bioprocess weakness By Investing.com - Investing.com South Africa
Stifel cuts Danaher stock price target on bioprocess weakness - Investing.com UK
Danaher Posts Mixed Q2 Results, Outlook for 2027 and Beyond Strengthened, RBC Says - marketscreener.com
Don't quit on Danaher stock after horrific earnings reaction - MSN
TD Cowen cuts Danaher stock price target on bioproduction timing - Investing.com
Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Guggenheim cuts Danaher stock price target to $200 on bioprocessing concerns - Investing.com Nigeria
Danaher Q2 2026 Deep Dive: EPS Beats by 4.9%, Revenue Up 6% - AlphaStreet
Cepheid to Unveil Third-Generation GeneXpert® System at ADLM 2026, Advancing Molecular Diagnostic Capabilities - PR Newswire
Deutsche Bank Adjusts Danaher Price Target to $240 From $250, Maintains Buy Rating - marketscreener.com
Danaher Stock Fell 11% After Earnings. Here’s What Could Drive It in 2026 - TIKR.com
Danaher (NYSE:DHR) Returns To Value Stock Focus After Results Update - Kalkine Media
Danaher revenue up 5.5% to USD 6.3B in Q2 2026 - Medical Buyer
Danaher Shares Drop 11% After Biotech Division Growth Falls Short of Expectations, Forcing Valuation Adjustment - TechStock²
Danaher (DHR) Experiences Notable Decline Amid Market Fluctuatio - GuruFocus
Leerink Partners Adjusts Price Target on Danaher to $240 From $270, Maintains Outperform Rating - Moomoo
Danaher’s Q2 Earnings Call Shows Life Sciences at Its Best Quarter in Years - TIKR.com
Wells Fargo Adjusts Price Target on Danaher to $195 From $212, Maintains Equalweight Rating - marketscreener.com
Danaher (DHR) Experiences Significant Decline - GuruFocus
Danaher Shares Slide 11% as Valuation Drops Following Biotech Growth Miss - TechStock²
Guggenheim Adjusts Price Target on Danaher to $200 From $235, Maintains Buy Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Danaher to $210 From $230, Maintains Buy Rating - marketscreener.com
Danaher (DHR) Reports Q3 Revenue Growth of 2%-3% Year-over-Year - GuruFocus
Don’t Quit on Danaher Stock After Horrific Earnings Reaction - Barron's
Key facts: Danaher strong cash; trims 2026 outlook; bio orders, $100M deferred - TradingView
Geopolitical Conflicts and Energy Shocks Cloud Danaher’s 2026 Financial Outlook - TipRanks
1.54%
2.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):